PMID- 21975431
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20221207
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 35
IP  - 6
DP  - 2012 Jun
TI  - Methylation status of CpG sites in the MCP-1 promoter is correlated to serum 
      MCP-1 in Type 2 diabetes.
PG  - 585-9
LID - 10.3275/7981 [doi]
AB  - AIM: Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine and plays 
      an important role in atherosclerosis of Type 2 diabetes. The aim of this study 
      was to investigate the methylation status of CpG sites in the MCP-1 promoter in 
      Type 2 diabetic patients and its correlation to serum MCP- 1 level, and blood 
      glucose level. METHODS: The 32 patients with Type 2 diabetes and 15 healthy 
      controls were enrolled into the study. Bodymass index, blood pressure, blood 
      lipid, blood glucose, glycosylated hemoglobin (HbA1c), and serum MCP-1 were 
      measured. Genomic DNA was isolated fromthe peripheral blood mononuclear cells 
      (PBMC). Methylation status of CpG sites in theMCP-1 promoter was determined using 
      methylation specific polymerase chain reaction. RESULTS: The promoter region 
      (2890-3050 bp) was predominantly methylated in PBMC from controls.Methylation of 
      CpGmotifs were less methylated in the patients than in the controls (25% vs 80%; 
      p<0.001), while the level of MCP-1 in serum was higher in patients with Type 2 
      diabetes (193.95+/-74.96 vs 88.46+/-55.10; p<0.001). MCP-1 promoter methylation was 
      significantly correlated to serum MCP-1, HbA1c, fasting blood glucose, and 
      triglyceride. CONCLUSION: These data suggest that hypomethylation of CpG sites in 
      the MCP-1 promoter region may be affected by blood glucose and TG, which then 
      increase the serum MCP-1 level and may play a role in the vascular complications 
      of Type 2 diabetes.
FAU - Liu, Z H
AU  - Liu ZH
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Avenue Jiefang 1277#, Wuhan, Hubei, PR 
      China.
FAU - Chen, L L
AU  - Chen LL
FAU - Deng, X L
AU  - Deng XL
FAU - Song, H J
AU  - Song HJ
FAU - Liao, Y F
AU  - Liao YF
FAU - Zeng, T S
AU  - Zeng TS
FAU - Zheng, J
AU  - Zheng J
FAU - Li, H Q
AU  - Li HQ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111003
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Blood Glucose)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atherosclerosis/*etiology/pathology
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood/*genetics
MH  - CpG Islands/*genetics
MH  - *DNA Methylation
MH  - Diabetes Complications/etiology/pathology
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Promoter Regions, Genetic/*genetics
MH  - Triglycerides/metabolism
EDAT- 2011/10/07 06:00
MHDA- 2012/12/12 06:00
CRDT- 2011/10/07 06:00
PHST- 2011/10/07 06:00 [entrez]
PHST- 2011/10/07 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - 7981 [pii]
AID - 10.3275/7981 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2012 Jun;35(6):585-9. doi: 10.3275/7981. Epub 2011 Oct 3.